Rituximab vs placebo
Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
- OR 1.55 [0.06, 39.15]1 study · 104 participantsVery low